Clarus Therapeutics Holdings, Inc. Sustainability Profile
Clarus Therapeutics Holdings, Inc., a leading biopharmaceutical company based in the United States, focuses on developing innovative therapies for men’s health, particularly in hormone replacement. Founded in 2009, Clarus has made significant strides in the industry, notably with its flagship product, Jatenzo, which offers a unique oral testosterone replacement option, setting it apart from traditional injectable therapies. Headquartered in the US, Clarus operates primarily in North America, aiming to address the unmet needs of patients with testosterone deficiency. The company has established a strong market position, recognised for its commitment to advancing men's health through research and development. With a focus on patient-centric solutions, Clarus Therapeutics continues to drive innovation in the biopharmaceutical sector, contributing to improved quality of life for men facing hormonal challenges.
DitchCarbon Score
How does Clarus Therapeutics Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clarus Therapeutics Holdings, Inc.'s score of 23 is lower than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Clarus Therapeutics Holdings, Inc.'s reported carbon emissions
Clarus Therapeutics Holdings, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As such, Clarus Therapeutics has not established any significant commitments towards reducing its carbon footprint or addressing climate change. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. However, without specific data or commitments from Clarus Therapeutics, it remains unclear how the company aligns with these industry trends.
How Carbon Intensive is Clarus Therapeutics Holdings, Inc.'s Industry?
How Carbon Intensive is Clarus Therapeutics Holdings, Inc.'s Location?
Clarus Therapeutics Holdings, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Clarus Therapeutics Holdings, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
